Skip to main content
. 2019 Jan 30;116(10):4558–4566. doi: 10.1073/pnas.1815515116

Fig. 6.

Fig. 6.

CXCR4 inhibition improves outcome of ICBs. (A–C) Quantification of lung nodules in mice with spontaneous lung metastases arising from orthotopic breast tumors. Mice were treated with AMD3100 or saline (control) through an osmotic pump for 2 wk and with or without immune checkpoint blockades (α-CTLA-4 and α-PD-1) on days 2, 5, and 8. Lungs were collected and counted at the end point of the metastatic survival studies. Both AMD100 or combination therapy of AMD310 with immunotherapy mixture reduces metastatic nodules (E0771: *P = 0.011, MCa-M3C: *P = 0.0018, 4T1: *P = 0.001). By Student’s tests. Error bars indicate SEM. n = 7–10. (D–F) Kaplan–Meier survival analyses of metastatic setting study in mice with spontaneous lung metastases arising from orthotopic breast tumors, by log-rank tests. (D) Animal survival in mice with spontaneous E0771 lung metastases. The immunotherapy mixture improves median animal survival time by day 43 (**P < 001), and the combination with AMD3100 greatly extends the animal survival by curing four of seven mice (*P < 0.0001). n = 7. (E) Animal survival in mice with spontaneous MCa-M3C lung metastases. The immunotherapy mixture does not improve median animal survival time, but the combination with AMD3100 extends the animal survival by 76%, curing 2 of 10 mice (*P < 0.001). n = 9–10. (F) Animal survival in mice with spontaneous 4T1 lung metastases. The immunotherapy mixture does not improve median animal survival time, but the combination with AMD3100 extends the animal survival by 35% (*P = 0.055), curing 2 of 10 mice. n = 9–10.